Explore the words cloud of the SAMBAfun project. It provides you a very rough idea of what is the project "SAMBAfun" about.
The following table provides information about the project.
|Coordinator Country||Norway [NO]|
|Total cost||3˙688˙711 €|
|EC max contribution||2˙918˙312 € (79%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-12-01 to 2021-11-30|
Take a look of project's partnership.
|1||CARDIACCS AS||NO (Oslo)||coordinator||1˙107˙221.00|
|2||OSYPKA AG||DE (RHEINFELDEN BADEN)||participant||690˙375.00|
|3||AARHUS UNIVERSITET||DK (AARHUS C)||participant||487˙312.00|
|4||OSLO UNIVERSITETSSYKEHUS HF||NO (OSLO)||participant||454˙903.00|
|5||DEUTSCHES HERZZENTRUM BERLIN||DE (BERLIN)||participant||178˙500.00|
In patients undergoing open-heart surgeries, perioperative cardiac monitoring is used to track the functioning of the heart and identify complications. However, myocardial failure and other severe complications can escape detection using current monitoring technologies, given the trade-offs between invasiveness, real time measurements, accessibility and accuracy of data. Given the high-risk profile of these surgeries, failure to timely detect complications leads to increased mortality and morbidity, which in turn results in increased hospitalization costs and lower quality of life for the affected patients.
For effective cardiac monitoring, surgeons need real time data, 24h continuous monitoring during and post-surgery, and an accurate biosignal marker that can be trusted for immediate detection and assessment of cardiac events. No current technology enables this with low invasiveness and risk.
Cardiaccs (SME) and Osypka (SME) will bring to market a patented solution that involves adding a 3-axis accelerometer to a standard epicardial pace lead, which is routinely used for most cardiac surgical patients, to assess cardiac motion and contractility in real time, both during and after surgery – and up to 7 days. Data from CardiSense will appear on a monitor and an alert function will let surgeons and nurses know as soon as a complication is picked-up on the continuously analysed data.
SAMBAfun brings together 2 SMEs with complementary know-how, IPR and value chain positions. Cardiaccs patented the concept, whereas Osypka has 40 years of experience in developing cardiac pace leads. Osypka dominates the German market and has extensive ties to global distributors. Three leading research hospitals (Oslo, Aarhus and Berlin) will demonstrate the latest advances in this device, provide Key Opinion Leader input and contribute with multi-market, highly credible data for regulatory certification and health economic models to support reimbursement applications in all markets.
|Website||Websites, patent fillings, videos etc.||2020-03-06 19:00:23|
Take a look to the deliverables list in detail: detailed list of SAMBAfun deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAMBAFUN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SAMBAFUN" are provided by the European Opendata Portal: CORDIS opendata.